Repeat surgery is the ideal choice for degenerated bioprosthetic mitral valves.
Percutaneous valve‐in‐valve (ViV) replacement for the treatment of degenerated bioprostheses has emerged as an alternative to open surgery in patients who are at high risk of surgical complications.
Joseph et al have described the feasibility and long‐term outcomes of Melody ViV Implantation for bioprosthetic mitral valve dysfunction in high‐risk population.
